DRUG
DMF
Relapsing multiple sclerosis (FDA 2013), plaque psoriasis (EMA)
22 hypotheses across 6 therapeutic domains
CROSS-DOMAIN PATTERN
Same drug, multiple disease domains
DMF appears in hypotheses across 6 disease domains: ALS, Alzheimer, Glioblastoma, Pancreatic cancer, Rheumatoid arthritis, Type 2 diabetes. Shared mediators that recur across at least two of those domains: NRF2, Nrf2.
Aggregated from the catalog. Biological interpretation of any multi-indication mechanism would require independent validation — this is a structural observation only.
ALL HYPOTHESES
Repurposing candidates for DMF
ALS 3
| Mediator | Outcome | Score | Tier | Lit. status | Trial | |
|---|---|---|---|---|---|---|
| NRF2 | ALS | 0.230 | Mid | partial evidence | none | |
| NRF2 | antioxidant defense | 0.230 | Mid | reproduces known | none | |
| NRF2 | neurodegenerative processes | 0.208 | Mid | novel signal | none |
Alzheimer 1
| Mediator | Outcome | Score | Tier | Lit. status | Trial | |
|---|---|---|---|---|---|---|
| NRF2 | Alzheimer's disease | 0.230 | Mid | reproduces known | active |
Glioblastoma 1
| Mediator | Outcome | Score | Tier | Lit. status | Trial | |
|---|---|---|---|---|---|---|
| NRF2 | patient survival | 0.208 | Mid | partial evidence | none |
Pancreatic cancer 7
| Mediator | Outcome | Score | Tier | Lit. status | Trial | |
|---|---|---|---|---|---|---|
| NRF2 | chemoresistance | 0.271 | High | partial evidence | none | |
| Nrf2 | chemoresistance | 0.271 | High | partial evidence | none | |
| NRF2 | poor prognosis | 0.230 | Mid | reproduces known | none | |
| Nrf2 | poor prognosis | 0.230 | Mid | reproduces known | none | |
| NRF2 | 5-FU resistance | 0.208 | Mid | novel signal | none | |
| NRF2 | cell proliferation | 0.208 | Mid | reproduces known | none | |
| NRF2 | poor survival | 0.208 | Mid | partial evidence | none |
Rheumatoid arthritis 7
| Mediator | Outcome | Score | Tier | Lit. status | Trial | |
|---|---|---|---|---|---|---|
| Nrf2 | rheumatoid arthritis | 0.271 | High | reproduces known | completed | |
| Nrf2 | disease activity | 0.271 | High | reproduces known | active | |
| Nrf2 | toxicity of conventional anti-rheumatic therapies | 0.230 | Mid | novel signal | none | |
| Nrf2 | drug efflux | 0.230 | Mid | novel signal | none | |
| Nrf2 | efficacy of synthetic anti-rheumatic drugs | 0.230 | Mid | novel signal | none | |
| Nrf2 | interstitial lung disease | 0.230 | Mid | novel signal | none | |
| STAT3 | prurigo nodularis | 0.208 | Mid | novel signal | none |
Type 2 diabetes 3
| Mediator | Outcome | Score | Tier | Lit. status | Trial | |
|---|---|---|---|---|---|---|
| Nrf2 | type 1 diabetes | 0.230 | Mid | reproduces known | active | |
| Nrf2 | lipid accumulation | 0.208 | Mid | partial evidence | none | |
| Nrf2 | diabetic cardiomyopathy | 0.208 | Mid | partial evidence | none |